Loading...
Stem cell transplant for CML in the imatinib era
Tyrosine kinase inhibitor (TKI) therapy has revolutionized the therapy of CML. Thus, while in the near past allogeneic transplantation was the curative option for CML, imatinib, nilotinib, and dasatinib have pushed transplantation to the role of salvage therapy in CML. Still, TKI therapy still fails...
Saved in:
| Main Author: | |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3189478/ https://ncbi.nlm.nih.gov/pubmed/20875552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminhematol.2010.06.008 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|